Plain-English translation of NCT06232122 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing two advanced imaging scans—one using a newer tracer called 68Ga-FAPI-46 and one using a more traditional tracer called 18F-FDG—to find ovarian cancer that may have returned. The study focuses on women whose cancer appeared to be gone after treatment, but whose CA125 blood markers (a sign of cancer activity) are now rising. Researchers want to see if the newer imaging approach can detect cancer recurrence better than the standard approach alone.
When ovarian cancer CA125 levels start rising after treatment, it often means cancer is coming back—sometimes months before doctors can see it on regular scans. The standard imaging scan can miss some recurrences, so doctors need better tools to catch the cancer earlier when treatment options are still strong.
You likely qualify if…
You likely don't qualify if…
You would receive an injection of the new imaging tracer and then undergo a PET/CT scan—a type of imaging that shows both structure and activity in your body. This scan takes about 30 minutes and is painless. The study compares this newer approach with the standard imaging scan to see which one better finds any cancer that may have returned, helping doctors decide on your next steps.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Taiwan